The Semaphorin/Plexin signaling pathway is a major axon guidance system critical for neural circuit formation, synaptic plasticity, and neuronal survival.[1] Semaphorins are a large family of secreted and membrane-bound proteins that signal through Plexin receptors, regulating cytoskeletal dynamics, neurite outgrowth, and synaptic function throughout the central nervous system.[2] Originally characterized for their roles in neural development, semaphorin/plexin signaling has emerged as an important pathway in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.[3] [1:1]
The pathway's dual roles in developmental axon guidance and adult synaptic plasticity make it a compelling target for understanding neurodegeneration and developing therapeutic interventions. [2:1]
The Class 3 semaphorins are the primary secreted ligands for PlexinA receptors: [3:1]
SEMA3A (Semaphorin 3A): [4]
SEMA3B (Semaphorin 3B): [5]
SEMA3C (Semaphorin 3C): [^6]
SEMA3D (Semaphorin 3D): [^7]
SEMA3E (Semaphorin 3E): [^8]
SEMA3F (Semaphorin 3F): [^9]
| Ligand | Primary Receptor | Key Functions | [^10]
|--------|------------------|----------------|
| SEMA3A | PlexinA2, PlexinA4 | Cortical migration, memory |
| SEMA3B | PlexinA2, PlexinA3 | Tumor suppression, survival |
| SEMA3C | PlexinA2, PlexinA4 | Cortical guidance, plasticity |
| SEMA3D | PlexinA1, PlexinD1 | Sensory pathways |
| SEMA3E | PlexinD1 | Motor neuron guidance |
| SEMA3F | PlexinA3, NRP2 | Axonal repulsion |
Other semaphorin classes signal through different receptor combinations:
The PlexinA family (PlexinA1-A4) are the primary receptors for class 3 semaphorins:
PlexinA1 (PLXNA1):
PlexinA2 (PLXNA2):
PlexinA3 (PLXNA3):
PlexinA4 (PLXNA4):
PlexinB1 (PLXNB1):
Neuropilin-1 (NRP1):
Neuropilin-2 (NRP2):
| Receptor | Ligands | Expression | Key Functions |
|---|---|---|---|
| PlexinA1 | SEMA3A, SEMA3C | Cortex, hippocampus | Synaptic plasticity |
| PlexinA2 | SEMA3A, SEMA3F | Cortex, development | Cortical migration |
| PlexinA3 | SEMA3A-F | Excitatory neurons | Synaptic transmission |
| PlexinA4 | SEMA3A, SEMA3C | PNS, sensory | Pain, hearing |
| NRP1 | SEMA3A-F | Neurons, endothelium | Coreceptor |
| NRP2 | SEMA3C, SEMA3F | Hippocampus, sensory | Coreceptor |
Upon semaphorin binding to Plexin receptors:
Rho GTPase Family:
PI3K/Akt Pathway:
MAPK/ERK Pathway:
FAK/Paxillin Pathway:
Neuropilins enhance signaling through:
During brain development:
In mature neurons:
In Alzheimer's Disease, semaphorin/plexin signaling is dysregulated:[3:2][4:1]
| Evidence | Finding |
|---|---|
| Preclinical | SEMA3A levels elevated in AD hippocampus |
| Preclinical | PlexinA2 expression reduced in AD models |
| Preclinical | SEMA3A disrupts synaptic plasticity in Aβ models |
| Clinical | NRP1 genetic variants associated with AD risk |
| Clinical | Altered semaphorin signaling in AD brain tissue |
Key Mechanisms:
In Parkinson's Disease, semaphorin/plexin affects dopaminergic neurons:[4:2][5:1]
| Evidence | Finding |
|---|---|
| Preclinical | SEMA3A protects dopaminergic neurons from MPTP |
| Preclinical | PlexinA2 regulates dopaminergic axon guidance |
| Preclinical | NRP1 promotes dopaminergic neuron survival |
| Clinical | Altered SEMA3 expression in PD substantia nigra |
| Clinical | Semaphorin pathway genes in PD GWAS |
Key Mechanisms:
In ALS, semaphorin/plexin influences motor neuron biology:[5:2][^6]
| Evidence | Finding |
|---|---|
| Preclinical | SEMA3A promotes motor neuron survival |
| Preclinical | PlexinA4 variants linked to ALS risk |
| Preclinical | SEMA3A at neuromuscular junction |
| Clinical | Altered semaphorin expression in ALS spinal cord |
| Clinical | Neuropilin dysregulation in ALS motor cortex |
Key Mechanisms:
Semaphorin/plexin pathway modulators are being investigated for neuroprotective therapies.[^9]
Agonists and Activators:
Antagonists:
Modulators:
| Target | Approach | Development Stage |
|---|---|---|
| SEMA3A | Recombinant protein | Preclinical |
| SEMA3F | Gene therapy | Preclinical |
| PlexinA2 | Small molecule modulators | Preclinical |
| NRP1 | Blocking antibodies | Phase I (cancer) |
| NRP1/NRP2 | Dual antagonists | Preclinical |
The Semaphorin/Plexin signaling pathway represents a fundamental axon guidance system essential for nervous system development and function. Through its complex repertoire of ligands (SEMA3A-F and other classes) and receptors (PlexinA/B family with Neuropilin co-receptors), this pathway regulates neurite outgrowth, axon guidance, synaptic formation, and neuronal survival. In neurodegenerative diseases, dysregulation of semaphorin/plexin signaling contributes to pathology through impaired synaptic plasticity, reduced neuroprotection, and altered neuronal connectivity. The pathway's involvement in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis makes it an attractive target for therapeutic intervention. Understanding the spatiotemporal dynamics of semaphorin/plexin signaling and its interactions with other guidance systems provides opportunities for developing neuroprotective strategies.
This section highlights recent publications relevant to this mechanism.
A unifying mechanism for presynaptic homeostatic plasticity at mammalian peripheral and central synapses. ↩︎ ↩︎
'Disruption of Plexin-A1 signaling by FTX-101: mode of action and effect on oligodendrocyte biology'. ↩︎ ↩︎
'Semaphorin 3s signaling in the central nervous system: Mechanisms and therapeutic implication for brain diseases'. ↩︎ ↩︎ ↩︎
Molecular mechanisms of proteoglycan-mediated semaphorin signaling in axon guidance. ↩︎ ↩︎ ↩︎
Astrocyte-to-microglia communication via Sema4B-Plexin-B2 modulates injury-induced reactivity of microglia. ↩︎ ↩︎ ↩︎